Initial data from the low‐dose cohort of the ongoing Phase 1/2 trials, assessing the safety of intrathecal LX1001 administration, showed that LX1001 relatively raised the protective levels of CSF APOE2 in AD patients with APOE4 homozygotes and reduced core AD biomarkers in CSF (T‐tau and P‐tau) with no serious adverse events reported. Here, MAPT is linked to Alzheimer disease.